YEZTUGO (Lenacapavir Sodium) Patent Expiration, LOE Window & CMS Spending

YEZTUGO (Lenacapavir Sodium) by Gilead Sciences: FDA Orange Book core substance LOE 2039-07-15 (last listed 2040-11-25), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $14,109 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN220018 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-07-15
Last Listed Patent or Exclusivity Date2040-11-25
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($14,109 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.